Exenatide and the treatment of patients with Parkinson's disease
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
UNLABELLED: BACKGROUND. There is increasing interest in methods to more rapidly and cost-efficiently investigate drugs that are approved for clinical use in the treatment of another condition. Exenatide is a type 2 diabetes treatment that has been shown to have neuroprotective/neurorestorative properties in preclinical models of neurodegeneration. METHODS. As a proof of concept, using a single-blind trial design, we evaluated the progress of 45 patients with moderate Parkinson's disease (PD), randomly assigned to receive subcutaneous exenatide injection for 12 months or to act as controls. Their PD was compared after overnight withdrawal of conventional PD medication using blinded video assessment of the Movement Disorders Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS), together with several nonmotor tests, at baseline, 6 months, and 12 months and after a further 2-month washout period (14 months). RESULTS. Exenatide was well tolerated, although weight loss was common and l-dopa dose failures occurred in a single patient. Single-blinded rating of the exenatide group suggested clinically relevant improvements in PD across motor and cognitive measures compared with the control group. Exenatide-treated patients had a mean improvement at 12 months on the MDS-UPDRS of 2.7 points, compared with mean decline of 2.2 points in control patients (P = 0.037). CONCLUSION. These results demonstrate a potential cost-efficient approach through which preliminary clinical data of possible biological effects are obtainable, prior to undertaking the major investment required for double-blind trials of a potential disease-modifying drug in PD. TRIAL REGISTRATION: Clinicaltrials.gov NCT01174810. FUNDING: Cure Parkinson's Trust.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Three clinical trials consistently describe a slowed decline in motor function when using the short-acting GLP-1 receptor agonists exenatide and lixisenatide in people with Parkinson's disease; 102-104”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [103]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“According to preliminary clinical trials, patients treated with exenatide improved by 2.7 points on the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) after 12 months, compared to a decline of 2.2 points in control patients. 86”
From Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications (2024) · cites this paper as [86]
In the citing paper
“Another single-blind, phase 2 trial evaluated exenatide, which improved motor deficits in PD patients for more than 12 months.523”
From Antiageing strategy for neurodegenerative diseases: from mechanisms to clinical advances (2025) · cites this paper as [523]
In the citing paper
“Therefore, diabetes drugs such as GLP-1 are used to treat AD and PD, and have shown good efficacy (Aviles-Olmos et al. 2013; Gejl et al. 2016).”
From Therapeutic effect of GLP-1 engineered strain on mice model of Alzheimer’s disease and Parkinson’s disease (2020) · cites this paper as Aviles-Olmos et al. 2013
In the citing paper
“Currently, GLP-1 drugs have been used in AD and PD patients in clinical trials and have shown efficacy (Aviles-Olmos et al. 2013; Gejl et al. 2016).”
From Therapeutic effect of GLP-1 engineered strain on mice model of Alzheimer’s disease and Parkinson’s disease (2020) · cites this paper as Aviles-Olmos et al. 2013
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Systematic review of levodopa dose equivalency reporting in Parkinson's disease
Tomlinson, C. L., Stowe, R., Patel, S., Rick, C., Gray, R., & Clarke, C. E. (2010) · Movement Disorders · doi:10.1002/mds.23429 · Cited by 4,219
DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559 · cited 2×
“The frequency of the adverse events in the exenatide group was similar to that seen in the previous clinical trials of exenatide in diabetes patients (4, 5).”
BackgroundResultWeaver, F. M. (2009) · JAMA · doi:10.1001/jama.2008.929 · Cited by 1,525
Buse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346
Eng, J., Kleinman, W. A., Singh, L., Singh, G., & Raufman, J. P. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)42531-8 · Cited by 1,000 · cited 1×
“The first of these, exendin-4, was discovered in the saliva of the Gila monster (3) and found to have beneficial effects on glucose homeostasis through stimulation of glucose level–dependent insulin release, islet cell proliferation, reduction of islet cell apoptosis, and weight loss (4, 5).”
BackgroundGlucagon-like peptide-1 receptor is involved in learning and neuroprotection
During, M. J., Cao, L., Zuzga, D. S., Francis, J. S., Fitzsimons, H. L., Jiao, X., Bland, R. J., Klugmann, M., Banks, W. A., Drucker, D. J., et al. (2003) · Nature Medicine · doi:10.1038/nm919 · Cited by 851
Li, Y., Perry, T., Kindy, M. S., Harvey, B. K., Tweedie, D., Holloway, H. W., Powers, K., Shen, H., Egan, J. M., Sambamurti, K., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806720106 · Cited by 589
(2004) · Archives of Neurology · doi:10.1001/archneur.61.7.1044 · Cited by 561 · cited 1×
“8) (23), although this can vary Table 4 Adverse events reported by trial participants”
BackgroundThe NINDS NET-PD Investigators (2006) · Neurology · doi:10.1212/01.wnl.0000201252.57661.e1 · Cited by 453
Kolterman, O. G., Kim, D. D., Shen, L., Ruggles, J. A., Nielsen, L. L., Fineman, M. S., & Baron, A. D. (2005) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/62.2.173 · Cited by 434
Cited by
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
Drucker, D. J. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.001 · Cited by 2,170
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647
“In clinical trials, exenatide improved the MDS-UPDRS score (a standardized assessment scale for patients with Parkinson’s disease) [230,231].”
BackgroundMicroglia in neurodegenerative diseases: mechanism and potential therapeutic targets
Gao, C., Jiang, J., Tan, Y., & Chen, S. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01588-0 · Cited by 1,616
“Exenatide, one of the most extensively studied GLP-1 receptor agonists, provided both motor and cognitive benefits in PD patients and was well tolerated.(493) Notably, the favorable effects lasted 12 months after treatment discontinuation.”
BackgroundBlock of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson’s disease
Yun, S. P., Kam, T.-I., Panicker, N., Kim, S., Oh, Y., Park, J.-S., Kwon, S.-H., Park, Y. J., Karuppagounder, S. S., Park, H., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0051-5 · Cited by 1,123
Athauda, D., Maclagan, K., Skene, S. S., Bajwa-Joseph, M., Letchford, D., Chowdhury, K., Hibbert, S., Budnik, N., Zampedri, L., Dickson, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31585-4 · Cited by 889
Self-citationBDNF mediates adaptive brain and body responses to energetic challenges
Marosi, K., & Mattson, M. P. (2014) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2013.10.006 · Cited by 568
“gov NCT01255163, NCT01469351, and NCT01843075) with promising initial results in PD patients [69].”
GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects
Zhao, X., Wang, M., Wen, Z., Lu, Z., Cui, L., Fu, C., Xue, H., Liu, Y., & Zhang, Y. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.721135 · Cited by 463
“complex I and the anti-apoptotic protein Bcl-2 (72), while longterm use of exendin-4 in rodents promoted the function of hippocampal nerves, and improved motor function and behavior (73).”
BackgroundProgress towards therapies for disease modification in Parkinson's disease
Vijiaratnam, N., Simuni, T., Bandmann, O., Morris, H. R., & Foltynie, T. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00061-2 · Cited by 419
Self-citationButterfield, D. A., Di Domenico, F., & Barone, E. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.06.010 · Cited by 402
“2 points in control patients [223]”
Graaf, C. D., Donnelly, D., Wootten, D., Lau, J., Sexton, P. M., Miller, L. J., Ahn, J.-M., Liao, J., Fletcher, M. M., Yang, D., et al. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011395 · Cited by 403
“Recently, a single-blind clinical trial of exendin-4 in PD patients showed that exenatide was well tolerated, and the treated group exhibited clinically relevant improvements across motor and cognitive measures compared with the control group (Aviles-Olmos et al., 2013).”
ResultSchapira, A. H. V., Olanow, C. W., Greenamyre, J. T., & Bezard, E. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61010-2 · Cited by 392
Athauda, D., & Foltynie, T. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.01.013 · Cited by 383
“Lancet 381, 117–124 246 Aviles-Olmos, I. et al. (2013) Exenatide and the treatment of patients with Parkinson’s disease.”
BackgroundSelf-citationEfficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity
Drucker, D. J. (2024) · Diabetes Care · doi:10.2337/dci24-0003 · Cited by 383
Chen, Z., Li, G., & Liu, J. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104700 · Cited by 363
Kim, B., & Feldman, E. L. (2015) · Experimental & Molecular Medicine · doi:10.1038/emm.2015.3 · Cited by 355
Trial of Lixisenatide in Early Parkinson’s Disease
Meissner, W. G., Remy, P., Giordana, C., Maltête, D., Derkinderen, P., Houéto, J.-L., Anheim, M., Benatru, I., Boraud, T., Brefel-Courbon, C., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2312323 · Cited by 369
Self-citationAnti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications
Alharbi, S. H. (2024) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188231222367 · Cited by 358
“86 Exenatide has also exhibited the potential to lessen brain deterioration and disability in patients with MS. 87 Furthermore, lixisenatide has been tested for amyotrophic lateral sclerosis, showing promise in slowing disease advancement and enhancing survival.”
BackgroundOld Drugs as New Treatments for Neurodegenerative Diseases
Durães, F., Pinto, M., & Sousa, E. (2018) · Pharmaceuticals · doi:10.3390/ph11020044 · Cited by 343
Insulin resistance and Parkinson’s disease: A new target for disease modification?
Athauda, D., & Foltynie, T. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.10.001 · Cited by 328
“A growing body of epidemiological and clinical data suggest that Parkinson’s disease and Type 2 diabetes (T2DM), both age-related diseases, share these similar dysregulated pathways(AvilesOlmos et al., 2013b; Santiago and Potashkin, 2014), suggesting common underlying pathological mechanisms.”
Self-citationInsulin, IGF-1 and GLP-1 signaling in neurodegenerative disorders: Targets for disease modification?
Bassil, F., Fernagut, P.-O., Bezard, E., & Meissner, W. G. (2014) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2014.02.005 · Cited by 309
Pleiotropic Effects of GLP-1 and Analogs on Cell Signaling, Metabolism, and Function
Rowlands, J., Heng, J., Newsholme, P., & Carlessi, R. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00672 · Cited by 302
“Despite lacking a placebo-control in this study, the blinded ratings were indicative of clinical improvement in both motor and cognitive measures compared to control (277, 278).”
ResultMotor and Cognitive Advantages Persist 12 Months After Exenatide Exposure in Parkinson’s Disease
Aviles-Olmos, I., Dickson, J., Kefalopoulou, Z., Djamshidian, A., Kahan, J., Ell, P., Whitton, P., Wyse, R., Isaacs, T., Lees, A., et al. (2014) · Journal of Parkinson's Disease · doi:10.3233/jpd-140364 · Cited by 299
“The trial methods have been described in detail previously [10].”
MethodResultSelf-citationCukierman-Yaffe, T., Gerstein, H. C., Colhoun, H. M., Diaz, R., García-Pérez, L.-E., Lakshmanan, M., Bethel, A., Xavier, D., Probstfield, J., Riddle, M. C., et al. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30173-3 · Cited by 300
Kopp, K. O., Glotfelty, E. J., Li, Y., & Greig, N. H. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106550 · Cited by 298
Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases
Hölscher, C. (2014) · Journal of Endocrinology · doi:10.1530/joe-13-0221 · Cited by 288
“Most interestingly, exendin-4 showed a clear improvement in the Mattis dementia rating scale 2 (DRS-2) cognitive score, suggesting that exendin-4 has beneficial effects in the CNS on cognition and memory (Aviles-Olmos et al. 2013).”
BackgroundRegulation of Glucose Homeostasis by GLP-1
Nadkarni, P., Chepurny, O. G., & Holz, G. G. (2014) · Progress in Molecular Biology and Translational Science · doi:10.1016/b978-0-12-800101-1.00002-8 · Cited by 287
Microglial phenotypes in Parkinson’s disease and animal models of the disease
Joers, V., Tansey, M. G., Mulas, G., & Carta, A. R. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.04.006 · Cited by 285
“In this pilot study, exenatide group suggested clinically relevant improvements across motor and cognitive measures as compared with the control group (NCT01174810) (Aviles-Olmos et al., 2013; Foltynie and Aviles-Olmos, 2014).”
ResultThe ongoing pursuit of neuroprotective therapies in Parkinson disease
Athauda, D., & Foltynie, T. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.226 · Cited by 269
Self-citationThe Impact of Disease Comorbidities in Alzheimer’s Disease
Santiago, J. A., & Potashkin, J. A. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.631770 · Cited by 259
“Exendin-4 (exenatide), a GLP-1 receptor agonist, has been shown to improve motor symptoms in PD clinical trials (Aviles-Olmos et al., 2013; Athauda et al., 2017).”
BackgroundRole of metabolism in neurodegenerative disorders
Procaccini, C., Santopaolo, M., Faicchia, D., Colamatteo, A., Formisano, L., de Candia, P., Galgani, M., De Rosa, V., & Matarese, G. (2016) · Metabolism · doi:10.1016/j.metabol.2016.05.018 · Cited by 258
Disease‐modifying strategies for Parkinson's disease
Kalia, L. V., Kalia, S. K., & Lang, A. E. (2015) · Movement Disorders · doi:10.1002/mds.26354 · Cited by 251
“A single-center, randomized, single-blind, proof-of-concept trial enrolled 45 subjects with moderate PD to receive subcutaneous injections of exenatide for 12 months or to act as controls without placebo.(33) Weight loss was the most common adverse event among subjects treated with exenatide and resulted in withdrawal…”
BackgroundReich, N., & Hölscher, C. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.970925 · Cited by 248
GLP-1-based therapies for diabetes, obesity and beyond
Drucker, D. J. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01183-8 · Cited by 236
“Positive results, principally the halting of disease progression, were reported in trials of exenatide twice daily 136 , exenatide once weekly 137 and lixisenatide once daily 138 .”
Liu, W., Jalewa, J., Sharma, M., Li, G., Li, L., & Hölscher, C. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.06.054 · Cited by 246
“More importantly, a pilot study in patients with PD demonstrated encouraging protective effects (Aviles-Olmos et al., 2013; Aviles-Olmos et al., 2014).”
BackgroundBeyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1
Hammoud, R., & Drucker, D. J. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00783-3 · Cited by 244
“…small, randomized trials examined the effects of twice daily or once weekly exenatide versus conventional therapy for 12 months in people with moderate Parkinson disease without T2DM and demonstrated improved motor activity scores that persisted following discontinuation of exenatide 160,161 .”
The expanding incretin universe: from basic biology to clinical translation
Drucker, D. J., & Holst, J. J. (2023) · Diabetologia · doi:10.1007/s00125-023-05906-7 · Cited by 243
Diabetes medications and risk of Parkinson’s disease: a cohort study of patients with diabetes
Brauer, R., Wei, L., Ma, T., Athauda, D., Girges, C., Vijiaratnam, N., Auld, G., Whittlesea, C., Wong, I., & Foltynie, T. (2020) · Brain · doi:10.1093/brain/awaa262 · Cited by 233
“Several small clinical studies have been conducted exploring the potential of repurposing GLP-1 mimetics to slow down the progression of Parkinson’s disease (Aviles-Olmos et al., 2013; Athauda et al., 2017).”
BackgroundSelf-citationThe Association Between Type 2 Diabetes Mellitus and Parkinson’s Disease
Cheong, J. L. Y., de Pablo-Fernandez, E., Foltynie, T., & Noyce, A. J. (2020) · Journal of Parkinson's Disease · doi:10.3233/jpd-191900 · Cited by 230
Self-citationGlycation potentiates α-synuclein-associated neurodegeneration in synucleinopathies
Vicente Miranda, H., Szegő, É. M., Oliveira, L. M. A., Breda, C., Darendelioglu, E., de Oliveira, R. M., Ferreira, D. G., Gomes, M. A., Rott, R., Oliveira, M., et al. (2017) · Brain · doi:10.1093/brain/awx056 · Cited by 226
“Strikingly, a recent clinical trial revealed that a drug used to treat diabetes resulted in improvements in both motor and cognitive metrics in Parkinson’s disease subjects (Aviles-Olmos et al., 2013).”
BackgroundInsulin Resistance as a Link between Amyloid-Beta and Tau Pathologies in Alzheimer’s Disease
Mullins, R. J., Diehl, T. C., Chia, C. W., & Kapogiannis, D. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00118 · Cited by 216
Phase I/II trial of iPS-cell-derived dopaminergic cells for Parkinson’s disease
Sawamoto, N., Doi, D., Nakanishi, E., Sawamura, M., Kikuchi, T., Yamakado, H., Taruno, Y., Shima, A., Fushimi, Y., Okada, T., et al. (2025) · Nature · doi:10.1038/s41586-025-08700-0 · Cited by 202
“In the remaining two patients (PD05 and PD06), motor deficits stabilized at a similar level of decline to those receiving conventional medication 36,37 .”
Hölscher, C. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.01.040 · Cited by 198
Ghosh, A., Tyson, T., George, S., Hildebrandt, E. N., Steiner, J. A., Madaj, Z., Schulz, E., Machiela, E., McDonald, W. G., Escobar Galvis, M. L., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aag2210 · Cited by 189
“A safety and efficacy trial of the antidiabetic agent, exendin-4, a glucagon-like peptide-1 agonist, suggested a reduction in motor and cognitive decline in PD patients, which was maintained even 12 months after cessation of treatment (65, 66).”
BackgroundSalameh, T. S., Rhea, E. M., Talbot, K., & Banks, W. A. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114187 · Cited by 188
“The single IRAs thus far demonstrating the greatest promise as AD and/or PD therapeutics are the FDA approved GLP-1 receptor agonists (GLP-1RAs) exendin-4 (Byetta®) [42, 43, 56-58, 65-67, 84], liraglutide (Victoza®) [36-41, 43, 48-50, 53, 85], lixisenatide (Adlyxin® in the U.”
BackgroundVijiaratnam, N., Girges, C., Auld, G., McComish, R., King, A., Skene, S. S., Hibbert, S., Wong, A., Melander, S., Gibson, R., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(24)02808-3 · Cited by 181
Self-citationBrain insulin resistance: role in neurodegenerative disease and potential for targeting
Hölscher, C. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1738383 · Cited by 180
Antidiabetic agents as a novel treatment for Alzheimer’s and Parkinson’s disease
Nowell, J., Blunt, E., Gupta, D., & Edison, P. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.101979 · Cited by 179
Timper, K., del Río-Martín, A., Cremer, A. L., Bremser, S., Alber, J., Giavalisco, P., Varela, L., Heilinger, C., Nolte, H., Trifunovic, A., et al. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.05.001 · Cited by 170
Zhang, L., Zhang, L., Li, L., & Hölscher, C. (2019) · Journal of Parkinson's Disease · doi:10.3233/jpd-181503 · Cited by 173
“Exendin-4 was protective in a pilot clinical trial in PD patients (NCT01174810) [22, 23].”
Glucagon-like Peptide-1 and the Central/Peripheral Nervous System: Crosstalk in Diabetes
Muscogiuri, G., DeFronzo, R. A., Gastaldelli, A., & Holst, J. J. (2017) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2016.10.001 · Cited by 171
The multifaceted pyruvate metabolism: role of the mitochondrial pyruvate carrier
Zangari, J., Petrelli, F., Maillot, B., & Martinou, J.-C. (2020) · Biomolecules · doi:10.3390/biom10071068 · Cited by 172
McClean, P. L., & Hölscher, C. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.07.015 · Cited by 170
Antiageing strategy for neurodegenerative diseases: from mechanisms to clinical advances
Jiang, Q., Liu, J., Huang, S., Wang, X.-Y., Chen, X., Liu, G.-H., Ye, K., Song, W., Masters, C. L., Wang, J., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02145-7 · Cited by 165
“523 Although the relationship between metformin and AD is contradictory, several clinical studies suggest that long-term metformin therapy is associated with a lower risk of neurodegenerative diseases.”
Delayed gastric emptying in Parkinson's disease
Marrinan, S., Emmanuel, A. V., & Burn, D. J. (2014) · Movement Disorders · doi:10.1002/mds.25708 · Cited by 156
“More recently a proof of concept study of the GLP-1 agonist exenatide in 45 patients with moderate PD reported improvements in motor function over 12 months of treatment.(33) Alpha-Synuclein and the Stomach in PD”
BackgroundSeufert, J., & Gallwitz, B. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12251 · Cited by 156
“Improvement in Parkinson’s rating scale Clinical Exenatide BID [80]”
BackgroundDiabetes drugs and neurological disorders: new views and therapeutic possibilities
Patrone, C., Eriksson, O., & Lindholm, D. (2013) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70125-6 · Cited by 161
Pathogenesis-Targeted, Disease-Modifying Therapies in Parkinson Disease
AlDakheel, A., Kalia, L. V., & Lang, A. E. (2013) · Neurotherapeutics · doi:10.1007/s13311-013-0218-1 · Cited by 181
“A proof-of-concept single blind trial design was conducted in PD [144] and this treatment will almost certainly be pursued for potential disease-modifying effects.”
BackgroundZhang, L., Zhang, L., Li, L., & Hölscher, C. (2018) · Neuropeptides · doi:10.1016/j.npep.2018.07.003 · Cited by 148
Anti-Inflammatory Effects of GLP-1 Receptor Activation in the Brain in Neurodegenerative Diseases
Diz-Chaves, Y., Mastoor, Z., Spuch, C., González-Matías, L. C., & Mallo, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179583 · Cited by 148
Protective properties of GLP‐1 and associated peptide hormones in neurodegenerative disorders
Hölscher, C. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15508 · Cited by 145
“There was a clear improvement in the exendin-4 group, whereas the control group deteriorated rapidly (Aviles-Olmos et al., 2013).”
BackgroundG lycation in P arkinson's disease and Alzheimer's disease
Miranda, H. V., El‐Agnaf, O. M. A., & Outeiro, T. F. (2016) · Movement Disorders · doi:10.1002/mds.26566 · Cited by 153
“Furthermore, a controlled human trial in PD patients treated with exenatide, a synthetic form of exendin-4, showed promising results with clear motor and cognitive advantages.(131) These effects persisted even 12 months after exenatide exposure.”
BackgroundBrain Insulin Resistance in Alzheimer's Disease and its Potential Treatment with GLP-1 Analogs
Talbot, K. (2014) · Neurodegenerative Disease Management · doi:10.2217/nmt.13.73 · Cited by 138
Talbot, K., & Wang, H.-Y. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.12.007 · Cited by 140
“Hopes are raised by the reversal of cognitive decline observed recently in the first clinical trial of a GLP1 analog (exenatide) on a neurodegenerative disorder, namely Parkinson’s disease [127].”
BackgroundWuolikainen, A., Jonsson, P., Ahnlund, M., Antti, H., Marklund, S. L., Möritz, T., Forsgren, L., Andersen, P. M., & Trupp, M. (2016) · Molecular BioSystems · doi:10.1039/c5mb00711a · Cited by 148
Kim, D. S., Choi, H.-I., Wang, Y., Luo, Y., Hoffer, B. J., & Greig, N. H. (2017) · Cell Transplantation · doi:10.1177/0963689717721234 · Cited by 136
“Weight loss proved to be the most common concern, preventing the trial completion of 1 patient, and proved fully reversible on cessation of the drug in the open trial.(99,100) Likewise, weight loss was noted in the double-blind trial.”
BackgroundMethodResultInfluentialIncretin and insulin signaling as novel therapeutic targets for Alzheimer’s and Parkinson’s disease
Nowell, J., Blunt, E., & Edison, P. (2023) · Molecular Psychiatry · doi:10.1038/s41380-022-01792-4 · Cited by 136
“The 2013 exenatide proof-of-concept clinical trial involving 45 moderate PD patients displayed possible efficacy concerning part 3 of the Movement Disorders Society Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) [17].”
BackgroundInfluentialHong, C.-T., Chen, K.-Y., Wang, W., Chiu, J.-Y., Wu, D., Chao, T.-Y., Hu, C.-J., Chau, K.-Y., & Bamodu, O. (2020) · Cells · doi:10.3390/cells9030740 · Cited by 133
“Furthermore, several anti-glycemic agents, including exenatide, a glucagon-like peptide analogue, have exerted a disease-modifying effect on PD; exenatide is presently in phase III clinical trial as a neuroprotective drug for patients with PD [18,19].”
BackgroundTai, J., Liu, W., Li, Y., Li, L., & Hölscher, C. (2017) · Brain Research · doi:10.1016/j.brainres.2017.10.012 · Cited by 145
“There were clear improvements in the motor coordination as shown in the MDSUPDRS part 3 assessment, and cognition was improved as measured by the Mattis DRS-2 test battery that had been designed to evaluate cognitive impairments in PD patients (Aviles-Olmos et al., 2013).”
The best medicine? The influence of physical activity and inactivity on Parkinson's disease
LaHue, S. C., Comella, C. L., & Tanner, C. M. (2016) · Movement Disorders · doi:10.1002/mds.26728 · Cited by 132
“Appropriation of pharmaceuticals already in use to address components of MetS has resulted in multiple novel therapies currently under investigation.(61,109,118) Physical activity and exercise provide a low-cost and universally available adjunct to current therapies during a time of soaring medical expenditures.”
BackgroundResultGLP-1’s role in neuroprotection: a systematic review
Erbil, D., Eren, C. Y., Demirel, C., Küçüker, M. U., Solaroğlu, I., & Eser, H. Y. (2019) · Brain Injury · doi:10.1080/02699052.2019.1587000 · Cited by 126
McClean, P. L., Jalewa, J., & Hölscher, C. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2015.07.024 · Cited by 135
Nauck, M. A., Tuttle, K. R., Tschöp, M. H., & Blüher, M. (2026) · The Lancet · doi:10.1016/s0140-6736(25)02105-1 · Cited by 123
Current applications and limitations of surgical treatments for movement disorders
Krack, P., Martinez‐Fernandez, R., del Alamo, M., & Obeso, J. A. (2017) · Movement Disorders · doi:10.1002/mds.26890 · Cited by 122
“Indeed, long-term follow-up studies of DBS indicate that cognitive decline after surgery is part of the natural evolution of the disease rather than a side effect of stimulation.(46,53,55,130) The overall preference of the STN over the GPi resulted in a growing number of reports on STN-DBS–related cognitive and behavi…”
BackgroundScott, R. A., Freitag, D. F., Li, L., Chu, A. Y., Surendran, P., Young, R., Grarup, N., Stancáková, A., Chen, Y., Varga, T. V., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad3744 · Cited by 118
Self-citationInsulin resistance in Alzheimer's disease
Diehl, T., Mullins, R., & Kapogiannis, D. (2017) · Translational Research · doi:10.1016/j.trsl.2016.12.005 · Cited by 117
“Importantly, exenatide has demonstrated clinical effectiveness for Parkinson disease, in terms of motor, but also cognitive performance measures.(233) Based on this evidence, our team conducts a phase II clinical trial of exenatide in MCI/early AD (NCT01255163).”
MethodFeng, P., Zhang, X., Li, D., Ji, C., Yuan, Z., Wang, R., Xue, G., Li, G., & Hölscher, C. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.02.012 · Cited by 120
“The GLP-1 mimetic exendin4 showed impressive effects in a pilot clinical study and in a phase II double blind, placebo controlled study in PD patients (Athauda et al., 2017; Aviles-Olmos et al., 2013a, 2014).”
Pharmacological Treatment of Parkinson’s Disease
Zahoor, I., Shafi, A., & Haq, E. (2018) · Codon Publications eBooks · doi:10.15586/codonpublications.parkinsonsdisease.2018.ch7 · Cited by 184
“Neuroprotective potential has been seen in preclinical models of the disease, with persistent clinical improvements observed in an initial clinical trial (84).”
BackgroundThe Relevance of Insulin Action in the Dopaminergic System
Fiory, F., Perruolo, G., Cimmino, I., Cabaro, S., Pignalosa, F. C., Miele, C., Beguinot, F., Formisano, P., & Oriente, F. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00868 · Cited by 111
GLP ‐1 receptor agonists: Nonglycemic clinical effects in weight loss and beyond
Ryan, D., & Acosta, A. (2015) · Obesity · doi:10.1002/oby.21107 · Cited by 112
“Although this study was not placebo-controlled, blinded ratings showed clinical improvement in exenatide-treated patients, compared to controls (79).”
Neuroprotective effects of geniposide in the MPTP mouse model of Parkinson's disease
Chen, Y., Zhang, Y., Li, L., & Hölscher, C. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.09.029 · Cited by 119
“A GLP-1 receptor agonist has shown good effects in animal models of PD, and also in a first clinical trial in PD patients (Aviles-Olmos et al., 2013; Aviles-Olmos et al., 2014; Holscher, 2014).”
BackgroundYuan, Z., Li, D., Feng, P., Xue, G., Ji, C., Li, G., & Hölscher, C. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.06.029 · Cited by 116
GLP-1 Receptor Agonists: A New Treatment in Parkinson’s Disease
Kalinderi, K., Papaliagkas, V. T., & Fidani, L. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25073812 · Cited by 130
Vadini, F., Simeone, P. G., Boccatonda, A., Guagnano, M. T., Liani, R., Tripaldi, R., Di Castelnuovo, A., Cipollone, F., Consoli, A., & Santilli, F. (2020) · International Journal of Obesity · doi:10.1038/s41366-020-0535-5 · Cited by 110
“Ongoing human trials reported or anticipate a neuroprotective effect of GLP-1-RAs in Parkinson’s and Alzheimer’s disease [41, 42].”
BackgroundProtective role of IGF-1 and GLP-1 signaling activation in neurological dysfunctions
Bhalla, S., Mehan, S., Khan, A., & Rehman, M. U. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104896 · Cited by 108
Insulin resistance and exendin-4 treatment for multiple system atrophy
Bassil, F., Canron, M.-H., Vital, A., Bezard, E., Li, Y., Greig, N. H., Gulyani, S., Kapogiannis, D., Fernagut, P.-O., & Meissner, W. G. (2017) · Brain · doi:10.1093/brain/awx044 · Cited by 107
Safety and tolerability of intracerebroventricular PDGF-BB in Parkinson’s disease patients
Paul, G., Zachrisson, O., Varrone, A., Almqvist, P., Jerling, M., Lind, G., Rehncrona, S., Linderoth, B., Bjartmarz, H., Shafer, L. L., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci79635 · Cited by 107
“In addition, the glucagonlike peptide-1 (GLP-1) agonist exendin-4 (exenatide) that also exhibits neuroprotective and neurogenic properties was investigated recently in an open-labeled, uncontrolled clinical study in patients with PD (4).”
Antidiabetic Drugs: Mechanisms of Action and Potential Outcomes on Cellular Metabolism
Meneses, M. J., Silva, B. M., Sousa, M., Sá, R., Oliveira, P. F., & Alves, M. G. (2015) · Current Pharmaceutical Design · doi:10.2174/1381612821666150710145753 · Cited by 132
“Exenatide has also been studied for the treatment of Parkinson’s disease [229, 230].”
BackgroundThe GLP-1 journey: from discovery science to therapeutic impact
Drucker, D. J. (2024) · Journal of Clinical Investigation · doi:10.1172/jci175634 · Cited by 126
Emerging Therapeutic Strategies for Parkinson’s Disease and Future Prospects: A 2021 Update
Gouda, N. A., Elkamhawy, A., & Cho, J. (2022) · Biomedicines · doi:10.3390/biomedicines10020371 · Cited by 119
α-Synuclein pathology as a target in neurodegenerative diseases
Park, H.-J., Kam, T., Dawson, V. L., & Dawson, T. M. (2024) · Nature Reviews Neurology · doi:10.1038/s41582-024-01043-w · Cited by 125
Li, Y., Bader, M., Tamargo, I., Rubovitch, V., Tweedie, D., Pick, C. G., & Greig, N. H. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13169 · Cited by 103
“Another pilot study on Ex-4, led by University College, London, has shown improved motor and cognitive symptoms in Parkinson’s patients in an openlabel trial and a 12-month follow-up study (NCT01174810) (Aviles-Olmos et al. 2013, 2014).”
BackgroundJi, C., Xue, G., Cao, L., Feng, P., Li, D., Li, L., Li, G., & Hölscher, C. (2015) · Brain Research · doi:10.1016/j.brainres.2015.09.035 · Cited by 105
“…receptor agonists also showed good neuroprotective effects in animal models of PD (Bertilsson et al., 2008; Harkavyi et al., 2008; Li et al., 2009; Liu et al., 2015; Zhang et al., 2015) and showed good effects in a pilot study in PD patients (Aviles-Olmos et al., 2013a; Aviles-Olmos et al., 2014).”
BackgroundCell and biomolecule delivery for tissue repair and regeneration in the central nervous system
Donaghue, I. E., Tam, R. Y., Sefton, M. V., & Shoichet, M. S. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.05.040 · Cited by 116
Svenningsson, P., Wirdefeldt, K., Yin, L., Fang, F., Markaki, I., Efendić, S., & Ludvigsson, J. F. (2016) · Movement Disorders · doi:10.1002/mds.26734 · Cited by 103
“A proof-of-concept study found a potential diseasemodifying effect of the glucagon-like peptide-1 (GLP-1)R agonist, exenatide, in Parkinson’s disease (PD).(1) GLP-1 is inactivated by dipeptidyl peptidase-4 (DPP-4).”
BackgroundGIP has neuroprotective effects in Alzheimer and Parkinson’s disease models
Zhang, Z. Q., & Hölscher, C. (2020) · Peptides · doi:10.1016/j.peptides.2019.170184 · Cited by 99
Current disease modifying approaches to treat Parkinson’s disease
Lindholm, D., Mäkelä, J., Di Liberto, V., Mudò, G., Belluardo, N., Eriksson, O., & Saarma, M. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-2101-1 · Cited by 99
“Most encouragingly, a clinical trial with exenatide, a GLP-1R agonist, given for 12 months to PD patients, showed that the drug favourably influenced motor and cognitive functions of patients with moderate disease [60].”
BackgroundAdvances in non-dopaminergic treatments for Parkinson's disease
Stayte, S., & Vissel, B. (2014) · Frontiers in Neuroscience · doi:10.3389/fnins.2014.00113 · Cited by 125
Parkinson’s disease and diabetes mellitus: common mechanisms and treatment repurposing
Labandeira, C. M., Bau, A. F., Ron, D. A., Álvarez, E., Alba, P. V., Garma, J. L., & Rodriguez-Perez, A. I. (2021) · Neural Regeneration Research · doi:10.4103/1673-5374.332122 · Cited by 104
“Animal models of NIRKO Table 1 | Summary of human clinical data involving the effects of anti-diabetic treatments in Parkinson’s disease Treatment Reference Results Exenatide Aviles-Olmos et al., 2013 Single-blind, 12 mon, Exenatide trial in 45 PD patients Significant benefit in motor (4.9 points difference, 95% CI: 0…”
BackgroundInfluentialHölscher, C. (2014) · Biochemical Society Transactions · doi:10.1042/bst20140016 · Cited by 96
Metadata
- Authors
- Aviles-Olmos, I., Dickson, J., Kefalopoulou, Z., Djamshidian, A., Ell, P., Soderlund, T., Whitton, P., Wyse, R., Isaacs, T., Lees, A., Limousin, P., & Foltynie, T.
- Affiliations
- University College London Hospitals NHS Foundation Trust (GB)
- UCL Queen Square Institute of Neurology (GB)
- UCL School of Pharmacy (GB)
- Cure Parkinson's Trust (GB)
- Corresponding author
- Foltynie, Thomas
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2013-05-20
- Volume
- 123
- Issue
- 6
- Pages
- 2730-2736
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC3668846
- OpenAlex
- W2123319002
- Cited by
- 529
- References
- 25
- Citations by year
- 2026: 40 · 2025: 64 · 2024: 56 · 2023: 30 · 2022: 38 · 2021: 36 · 2020: 33 · 2019: 30 · 2018: 39 · 2017: 33 · 2016: 40 · 2015: 36 · 2014: 38 · 2013: 15
- FWCI
- 27.31
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- National Institute for Health and Care Research
- University College London Hospitals NHS Foundation Trust
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Keywords
- exenatide, Parkinson's disease, drug repurposing, GLP-1 receptor agonists, neuroprotection, disease-modifying therapy, MDS-UPDRS, motor symptoms, cognitive function, non-motor symptoms, weight loss
- MeSH terms
- Exenatide, Aged, Antiparkinson Agents, Constipation, Female, Humans, Hypoglycemic Agents, Injections, Subcutaneous, Male, Middle Aged, Motor Activity, Parkinson Disease, Peptides, Venoms, Weight Loss, Disease Progression, Off-Label Use, Drug Repositioning
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.